Exabis Library
Welcome to the e-CCO Library!
P474: An enzyme-linked immunosorbent assay for therapeutic drug monitoring of vedolizumab
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P474: Analysis of UC colectomy rates in pre- and post-biologic era in South-East Scotland
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P474: Assessing the position of systemic tacrolimus in the treatment of inflammatory bowel disease: systematic review and meta-analysis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P474: Efficacy and safety of anti-TNF and vedolizumab in liver transplant recipients with inflammatory bowel disease (IBD)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P474: Postoperative disease course after appendectomy as experimental treatment for patients with therapy refractory moderate to severe ulcerative colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P474: Postoperative infectious complications in patients with Inflammatory Bowel Disease: experience of a tertiary center
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P474: Prevalence of fecal incontinence and clinical characteristics of IBD patients in remission and treated with biologics – experience from a tertiary referral center
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P475 Association between disease duration and degree of endoscopic improvement in patients with ulcerative colitis treated with tofacitinib
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P475: Gastroenterological and reumatological chronic patients: are there differences in individual welfare and quality of life?—a cross-observational study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P475: High prevalence of severe liver fibrosis in patients with longstanding IBD
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P475: Infections and malignancies during anti-TNF therapy in IBD patients affect all age groups – results from a 13-yr real-world retrospective study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P475: Profiling the use of Complementary Alternative Medicines among IBD patients
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P475: Rapid point-of-care anti-drug antibodies measurement correlates with standardised T tests and facilitate a proactive therapeutic drug monitoring approach in IBD patients on anti-TNF-α maintenance therapy
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P475: Real world data on treatment success and drug persistence in anti-TNF therapy for ulcerative colitis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P475: Switching from infliximab originator to CT-P13 is not related to increased immunogenicity in IBD patients: a prospective case-control study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P476 Efficacy and safety of 2 vedolizumab IV regimens in patients with perianal fistulising Crohn’s disease: results of the ENTERPRISE study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P476: Characterization of cardiac conduction abnormalities reported in the phase 3 ELEVATE programme
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P476: Combined therapy with adalimumab and mesenchymal stromal cells contributes to reduction in the degree of inflammation in ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P476: Disease recurrence patterns in patients undergoing bowel resections for Crohn’s disease.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P476: Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM